Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of QLG1130 (olanzapine + samidorphan) in adult schizophrenia
CTR20243849Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine + samidorphan in schizophrenia, sponsored by Qilu Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20243849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243849.